Sign in

Trial result ·

Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This trial looked at people with type 2 diabetes. All had heart and blood vessel disease, or a high risk of it. By chance, people got an SGLT2 inhibitor, a GLP-1 receptor agonist, or both. They used their own health insurance to get the drugs. This report covers the early test phase of the PRECIDENTD trial.

What they found

Of 173 people, 113 got one drug and 60 got both. At 4 months, fewer people on both drugs had filled their drugs. This gap was still seen over a median follow-up of 10 months. Of those who filled, more on both drugs stopped a study drug. Side effects were the main reason for stopping. Scores on body and mental health surveys did not change.

What it means for patients

The authors say starting and staying on both drugs was hard. This was true even with efforts to help people get the drugs. They say these hurdles make using both drugs together a challenge in type 2 diabetes.

Why it is not certain yet

This report covers only the early test phase of the trial. It includes only people who had health insurance. The abstract does not give results on heart or kidney health. The groups were not the same size, with 113 and 60 people.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.

PubMed · PMID 41456635

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Type 2 diabetes publications